F. Du

Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma

K. Boudjema, Y. Rolland, M. Latournerie, 2015, Clinical nuclear medicine.

Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma

J. Raoul, J. Edeline, O. Audrain, 2012, Acta oncologica.

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

T. Petit, J. Prevost, J. Pierga, 2020, EClinicalMedicine.

58P Detection of PIK3CA mutations in plasma ctDNA by Crystal Digital PCR for the selection of alpelisib treatment in routine clinical practice in advanced breast cancer patients

V. Quillien, J. Corne, A. Brunot, 2020 .

Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

F. André, M. Lacroix-Triki, T. Petit, 2022, Cancer Research.

Breast Cancer Biomarkers: Utility in Clinical Practice

N. Ueno, A. González-Angulo, F. Du, 2013, Current Breast Cancer Reports.